LLY

746.35

-1.09%↓

JNJ

177.3

-0.44%↓

ABBV

216.24

-0.94%↓

UNH

348.85

-1.15%↓

AZN

77.92

-2.04%↓

LLY

746.35

-1.09%↓

JNJ

177.3

-0.44%↓

ABBV

216.24

-0.94%↓

UNH

348.85

-1.15%↓

AZN

77.92

-2.04%↓

LLY

746.35

-1.09%↓

JNJ

177.3

-0.44%↓

ABBV

216.24

-0.94%↓

UNH

348.85

-1.15%↓

AZN

77.92

-2.04%↓

LLY

746.35

-1.09%↓

JNJ

177.3

-0.44%↓

ABBV

216.24

-0.94%↓

UNH

348.85

-1.15%↓

AZN

77.92

-2.04%↓

LLY

746.35

-1.09%↓

JNJ

177.3

-0.44%↓

ABBV

216.24

-0.94%↓

UNH

348.85

-1.15%↓

AZN

77.92

-2.04%↓

Search

ESPERION THERAPEUTICS INC

Atvērts

SektorsVeselības aprūpe

2.8 -1.41

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

2.76

Max

2.88

Galvenie mērījumi

By Trading Economics

Ienākumi

28M

-13M

Pārdošana

17M

82M

EPS

-0.206

Peļņas marža

-15.446

Darbinieki

304

EBITDA

37M

16M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt

Prognoze 12 mēnešiem

+152.46% upside

Dividendes

By Dow Jones

Nākamie ieņēmumi

2025. g. 6. nov.

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

211M

506M

Iepriekšējā atvēršanas cena

4.21

Iepriekšējā slēgšanas cena

2.8

Ziņu noskaņojums

By Acuity

10%

90%

9 / 371 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Bearish Evidence

ESPERION THERAPEUTICS INC Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 12. sept. 22:41 UTC

Galvenie tirgus virzītāji

GlucoTrack Stock Falls on Plans to Sell $3 Million Note

2025. g. 12. sept. 16:04 UTC

Galvenie tirgus virzītāji

Upexi Shares Climb on Solana Gains

2025. g. 14. sept. 23:48 UTC

Tirgus saruna

Oil Futures Mixed Amid Divergent Signals -- Market Talk

2025. g. 14. sept. 23:41 UTC

Tirgus saruna

Gold Edges Lower on Likely Technical Correction -- Market Talk

2025. g. 14. sept. 23:38 UTC

Tirgus saruna

China's Economic Activity Data May Continue Reflecting Slowdown -- Market Talk

2025. g. 14. sept. 23:13 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2025. g. 14. sept. 23:13 UTC

Tirgus saruna

Global Energy Roundup: Market Talk

2025. g. 14. sept. 23:13 UTC

Tirgus saruna

Infratil May Need to Be More Aggressive With Asset Sales -- Market Talk

2025. g. 14. sept. 23:13 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2025. g. 14. sept. 23:04 UTC

Tirgus saruna

Aristocrat's Interactive Unit Appears in Safe Hands -- Market Talk

2025. g. 13. sept. 08:20 UTC

Tirgus saruna
Peļņas

Tech, Media & Telecom Roundup: Market Talk

2025. g. 12. sept. 20:50 UTC

Tirgus saruna
Peļņas

Tech, Media & Telecom Roundup: Market Talk

2025. g. 12. sept. 20:50 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2025. g. 12. sept. 20:09 UTC

Peļņas

Correction to Opendoor Is Sliding. Don't Call It a Meme Stock, Says New Chairman. -- Barrons.com

2025. g. 12. sept. 19:23 UTC

Tirgus saruna

Oil Futures End Volatile Week With Moderate Gains -- Market Talk

2025. g. 12. sept. 19:16 UTC

Tirgus saruna

Oil Futures End Volatile Week With Moderate Gains -- Market Talk

2025. g. 12. sept. 19:03 UTC

Tirgus saruna

Natural Gas Futures Held Back By Plump Inventories -- Market Talk

2025. g. 12. sept. 18:59 UTC

Tirgus saruna

Dollar Pares Gains as Economy Keeps Showing Signs of Cooling -- Market Talk

2025. g. 12. sept. 18:38 UTC

Tirgus saruna
Peļņas

Adobe Seen Reaching Turning Point in AI Cycle -- Market Talk

2025. g. 12. sept. 18:33 UTC

Tirgus saruna

U.S. Oil Rig Count Rises By 2 to 416 -- Market Talk

2025. g. 12. sept. 18:22 UTC

Tirgus saruna

Canada's Divergence With US On Capex Spending is 'Appalling' -- Market Talk

2025. g. 12. sept. 16:56 UTC

Tirgus saruna

Renewable Fuels Association Calls for Nationwide E15 Following WASDE -- Market Talk

2025. g. 12. sept. 16:22 UTC

Peļņas

Adobe Earnings Were 'Solid.' Long-Term Growth Concerns Remain. -- Barrons.com

2025. g. 12. sept. 16:20 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2025. g. 12. sept. 16:19 UTC

Iegādes, apvienošanās, pārņemšana

These Stocks Are Moving the Most Today: Warner Bros., Paramount Skydance, Tesla, Super Micro, Microsoft, Figure Technology, and More -- Barrons.com

2025. g. 12. sept. 16:15 UTC

Tirgus saruna

Global Commodities Roundup: Market Talk

2025. g. 12. sept. 16:11 UTC

Peļņas

Novartis Catches a 'Sell.' Goldman Sachs Says the Stock Is Overvalued. -- Barrons.com

2025. g. 12. sept. 15:37 UTC

Tirgus saruna

Gold Holds Near All-Time Highs Ahead of Fed Meeting Next Week -- Market Talk

2025. g. 12. sept. 15:22 UTC

Tirgus saruna

European Gas Lifted by Geopolitical Risks But Storage Levels Ease Supply Fears -- Market Talk

2025. g. 12. sept. 15:07 UTC

Iegādes, apvienošanās, pārņemšana

These Stocks Are Moving the Most Today: Warner Bros., Paramount Skydance, Tesla, Super Micro, Microsoft, Figure Technology, and More -- Barrons.com

Salīdzinājums

Cenas izmaiņa

ESPERION THERAPEUTICS INC Prognoze

Cenas mērķis

By TipRanks

152.46% augšup

Prognoze 12 mēnešiem

Vidējais 7.17 USD  152.46%

Augstākais 16 USD

Zemākais 1.5 USD

Pamatojoties uz 3 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi ESPERION THERAPEUTICS INC — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

3 ratings

2

Pirkt

0

Turēt

1

Pārdot

Tehniskais rādītājs

By Trading Central

0.85 / 1.05Atbalsts un pretestība

Īstermiņā

Bearish Evidence

Vidējā termiņā

Weak Bullish Evidence

Ilgtermiņā

Strong Bearish Evidence

Noskaņojums

By Acuity

9 / 371 Rangs Veselības aprūpe

Ziņu noskaņojums

Ļoti spēcīga liecība "buļļu" tendencei

Volatilitāte

Zem vidējā

Ziņu apjoms (RCV)

Virs vidējā

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par ESPERION THERAPEUTICS INC

Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C. The company's products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. The company has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.
help-icon Live chat